Last data update: Mar 21, 2025. (Total: 48935 publications since 2009)
Records 1-10 (of 10 Records) |
Query Trace: Myrick A[original query] |
---|
Planning, development, design, and operation of the 2016 national culturally and linguistically appropriate services survey for office-based physicians
Myrick KL , Salvaggio M , Ejike-King L , Dunston SK , Dorsey-Johnson R , Khare M , Lau DT . Vital Health Stat 2025 2025 (67) Objectives This report describes the development and operations of the 2016 National Culturally and Linguistically Appropriate Services Survey for Office-based Physicians (National CLAS Physician Survey). The survey was developed to understand awareness, adoption, and implementation of the National CLAS Standards in health and health care among office-based physicians. Methods Survey development included a literature review of survey and assessment instruments that evaluated cultural and linguistic appropriateness in health care. Survey questions were pretested during a cognitive interview study of 20 office-based physicians in the District of Columbia metropolitan area. The cognitive interviews were analyzed using a grounded theory approach. The final survey was administered via web, mail, and computer-assisted telephone interview to 2, 400 sampled physicians between August 2016 and December 2016. A nonresponse bias assessment was conducted. Results The literature review identified five survey and assessment instruments. Collectively, survey content included: cultural competency training, cultural awareness, and adoption of the National CLAS Standards. Cognitive interviews showed respondent difficulty in question interpretation and survey completion of some items. Survey revisions addressed these issues. The final overall weighted survey response rate was 33.8%. Final weights produced a lower standardized bias than base weights. Conclusions The National CLAS Physician Survey is the first nationally representative survey to describe the use and implementation of culturally and linguistically appropriate services by office-based physicians. Data can serve as a baseline for future studies and as a benchmark for meeting the key objectives of the National CLAS Standards. © 2025, null. All rights reserved. |
Statewide outbreak of neisseria meningitidis serogroup Y, sequence type 1466 - Virginia, 2022-2024
Robinson M , Crain J , Kendall B , Alexander V , Diskin E , Saady D , Hicks C , Myrick-West A , Bordwine P , Sockwell D , Craig E , Rubis A , McNamara L , Sharma S , Howie R , Marasini D , Marjuki H , Colón A . MMWR Morb Mortal Wkly Rep 2024 73 (43) 973-977 ![]() ![]() Invasive meningococcal disease (IMD) is a severe illness that can have devastating effects; outbreaks are uncommon in the United States. Vaccination is the preferred control measure for IMD outbreaks when a defined population at risk (e.g., college students or persons experiencing homelessness) can be identified. In August 2022, the Virginia Department of Health (VDH) began investigating an IMD outbreak in Virginia's Eastern Health Planning Region, prompted by the detection of four confirmed cases within 8 weeks. Clinical isolates available from three cases were characterized as Neisseria meningitidis serogroup Y, sequence type 1466. A subsequent statewide investigation identified 36 genetically related cases, including seven deaths (case fatality rate = 19.4%) as of March 1, 2024. A majority of patients (63.9%) were in an age group (30-60 years) not generally considered at increased risk for IMD; 78.0% were non-Hispanic Black or African American. No common exposures, affiliations, or risk factors were identified, and a defined population could not be identified for vaccination. VDH recommended quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccination of a subset of close contacts of patients based on IMD risk factors and age range similar to that of patients with identified cases. IMD outbreaks might affect populations without established IMD risk factors. Lack of a well-defined population at risk might prompt exploration of novel control strategies, such as selective vaccination of close contacts. |
Local supports to break the cycle: A description of intersectional interventions to address adverse childhood experiences and drug overdose
Myrick AC , Adams CA , Cremer LJ , Filion N , Haddad S , Snyder C , Wisdom A . J Public Health Manag Pract 2024 CONTEXT: Adverse childhood experiences (ACEs), substance use disorders (SUDs), and overdose are interconnected issues impacting individuals and communities at multiple levels of the social ecology and across generations. Few studies describe approaches that intentionally and simultaneously address these issues. PROGRAM: This paper examines activities of 15 sites across the country that were designed to simultaneously prevent ACEs, SUD, and overdose. This paper describes the work at the intersection as well as gaps and opportunities. Describing ways to implement intersectional programming may assist other organizations in taking similar steps in their communities. IMPLEMENTATION: From December 2020 through July 15, 2023, funded sites received technical assistance from the National Association of County and City Health Officials and the Centers for Disease Control and Prevention for 18 months to support the implementation, adaptation, and/or expansion of evidence-based programs to address ACEs, SUD, and overdose. EVALUATION: Activities were coded to identify intersectional interventions that addressed ACEs, SUD, and overdose. Most of the ACEs prevention strategies and overdose prevention priority areas/guiding principles from which communities could choose were represented. Most activities were implemented with caregivers and families and addressed ACEs through interventions to lessen harm or to promote social norms. Primary prevention and coordination of resources were the most used overdose prevention priority area/guiding principle. DISCUSSION: It is possible to address the intersection of ACEs, SUD, and overdose on a local level. Opportunities to further address the intersection include incorporating more secondary and tertiary prevention strategies, expanding economic supports, and increasing the work focused on equity. |
The Martinsburg Initiative: A collaboration between public safety, public health, and schools to address trauma and substance use
Wisdom AC , Villamil V , Govindu M , Kursey M , Peppard L , Bates RA , Myrick A , Snyder C , Noonan RK . J Public Health Manag Pract 2022 28 S355-s358 The Martinsburg Initiative (TMI) is a community-based model developed in Martinsburg, West Virginia, that implements a comprehensive approach to adverse childhood experiences and substance use prevention and mitigation by leveraging partnerships in public health and health care, public safety, and education. TMI receives coordinated federal funding and technical assistance from the Centers for Disease Control and Prevention, the Washington-Baltimore High Intensity Drug Trafficking Agency, and the National Association of County and City Health Officials to integrate evidence-based and promising strategies. It advances such strategies by translating them for implementation within the community, evaluating the reach and potential impact of the model, and by engaging key stakeholders. Preliminary results describing program reach and short-term outcomes collected for a subset of the interventions during implementation are presented. The model uses touchpoints across multiple community sectors in the city of Martinsburg to break the cycle of trauma and substance use across the life span. |
Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018
Foster MA , Hofmeister MG , Albertson JP , Brown KB , Burakoff AW , Gandhi AP , Glenn-Finer RE , Gounder P , Ho PY , Kavanaugh T , Latash J , Lewis RL , Longmire AG , Myrick-West A , Perella DM , Reddy V , Stanislawski ES , Stoltey JE , Sullivan SM , Utah OF , Zipprich J , Teshale EH . MMWR Morb Mortal Wkly Rep 2021 70 (24) 875-878 During 1995-2011, the overall incidence of hepatitis A decreased by 95% in the United States from 12 cases per 100,000 population during 1995 to 0.4 cases per 100,000 population during 2011, and then plateaued during 2012─2015. The incidence increased by 294% during 2016-2018 compared with the incidence during 2013-2015, with most cases occurring among populations at high risk for hepatitis A infection, including persons who use illicit drugs (injection and noninjection), persons who experience homelessness, and men who have sex with men (MSM) (1-3). Previous outbreaks among persons who use illicit drugs and MSM led to recommendations issued in 1996 by the Advisory Committee on Immunization Practices (ACIP) for routine hepatitis A vaccination of persons in these populations (4). Despite these long-standing recommendations, vaccination coverage rates among MSM remain low (5). In 2017, the New York City Department of Health and Mental Hygiene contacted CDC after public health officials noted an increase in hepatitis A infections among MSM. Laboratory testing* of clinical specimens identified strains of the hepatitis A virus (HAV) that subsequently matched strains recovered from MSM in other states. During January 1, 2017-October 31, 2018, CDC received reports of 260 cases of hepatitis A among MSM from health departments in eight states, a substantial increase from the 16 cases reported from all 50 states during 2013-2015. Forty-eight percent (124 of 258) of MSM patients were hospitalized for a median of 3 days. No deaths were reported. In response to these cases, CDC supported state and local health departments with public health intervention efforts to decrease HAV transmission among MSM populations. These efforts included organizing multistate calls among health departments to share information, providing guidance on developing targeted outreach and managing supplies for vaccine campaigns, and conducting laboratory testing of clinical specimens. Targeted outreach for MSM to increase awareness about hepatitis A infection and improve access to vaccination services, such as providing convenient locations for vaccination, are needed to prevent outbreaks among MSM. |
Physician specialty and office visits made by adults with diagnosed multiple chronic conditions: United States, 2014-2015
Ward BW , Myrick KL , Cherry DK . Public Health Rep 2020 135 (3) 33354920913005 OBJECTIVES: Adults with multiple chronic conditions (MCCs; >/=2 chronic conditions) account for a substantial number of visits to health care providers. The complexity of a patient's care, including the number of chronic conditions, may differ by physician specialty. The objectives of this study were to (1) examine differences in physician office visits among adults with MCCs by physician specialty and (2) identify the types of MCC dyads (combinations of 2 chronic conditions) most common among visits to office-based physicians. METHODS: We used data from the 2014-2015 National Ambulatory Medical Care Survey (unweighted analytic sample, n = 61 682), a nationally representative survey of physician office-based ambulatory visits, to examine differences in physician office visits among adults with MCCs by physician specialty. We also identified the most commonly observed MCC dyads among these visits. RESULTS: During 2014-2015, 40.0% of physician office visits were made by adults with MCCs. Compared with visits for all specialties combined (40.0%), a significantly higher percentage of physician office visits among adults with MCCs were to specialists in cardiovascular disease (74.7%) and internal medicine (57.6%). For all physician specialties except psychiatry, the MCC dyads of hyperlipidemia and hypertension and diabetes and hypertension were among the most commonly observed MCC dyads among visits made by adults with MCCs. CONCLUSIONS: Awareness of these findings may help specialists improve care for adults with MCCs. The recognition among physicians of common MCC dyads is relevant to the care management of persons with MCCs. |
Evaluation of combination drug therapy for treatment of antibiotic resistant inhalation anthrax in a murine model
Heine HS , Shadomy SV , Boyer AE , Chuvala L , Riggins R , Kesterson A , Myrick J , Craig J , Candela MG , Barr JR , Hendricks K , Bower WA , Walke H , Drusano GL . Antimicrob Agents Chemother 2017 61 (9) Bacillus anthracis is considered a likely agent to be used as a bioweapon and use of a strain resistance to the first-line antimicrobial treatments is a concern. We determined treatment efficacy against a ciprofloxacin-resistant (Cr) strain of B. anthracis (Cr Ames) in a murine inhalational anthrax model. Ten groups of 46 BALB/c mice were exposed by inhalation to 7-35 LD50 of B. anthracis Cr Ames spores. Commencing at 36 hours (h) post-exposure, groups were administered intraperitoneal doses of sterile water for injections (SWI) and ciprofloxacinalone (control groups), or ciprofloxacin combined with two antimicrobials including meropenem/linezolid, meropenem/clindamycin, meropenem/rifampin, meropenem/doxycycline, penicillin/linezolid, penicillin/doxycycline, rifampin/linezolid, or rifampin/clindamycin at appropriate dosing intervals(6 or 12 hours) for the respective antibiotics. Ten mice per group were treated for 14 days and observed until day 28. Remaining animals were euthanized every 6-12h and blood, lungs, and spleens collected for lethal factor (LF) and/or bacterial load determinations. All combination groups showed significant survival over the SWI and ciprofloxacin controls: meropenem/linezolid (p=0.004), meropenem/clindamycin (p=0.005), meropenem/rifampin (p=0.012), meropenem/doxycycline (p=0.032), penicillin/doxycycline (p=0.012), penicillin/linezolid (p=0.026), rifampin/linezolid (p=0.001), and rifampin/clindamycin (p=0.032). In controls, blood, lung, and spleen bacterial counts increased to terminal endpoints. In combination treatment groups, blood and spleen bacterial counts showed low/no colonies after 24 hours treatment. LF fell below detection limits for all combination groups, yet remained elevated in control groups. Combinations with linezolid had the greatest inhibitory effect on mean LF levels. |
Beyond indicators: advances in global HIV monitoring and evaluation during the PEPFAR era
Porter LE , Bouey PD , Curtis S , Hochgesang M , Idele P , Jefferson B , Lemma W , Myrick R , Nuwagaba-Biribonwoha H , Prybylski D , Souteyrand Y , Tulli T . J Acquir Immune Defic Syndr 2012 60 Suppl 3 S120-6 Monitoring and evaluation (M&E) is fundamental to global HIV program implementation and has been a cornerstone of the President's Emergency Plan for AIDS Relief (PEPFAR). Rapid results were crucial to demonstrating feasibility and scalability of HIV care and treatment services early in PEPFAR. When national HIV M&E systems were nascent, the rapid influx of funds and the emergency expansion of HIV services contributed to the development of uncoordinated "parallel" information systems to serve donor demands for information. Close collaboration of PEPFAR with multilateral and national partners improved harmonization of indicators, standards, methods, tools, and reports. Concurrent PEPFAR investments in surveillance, surveys, program monitoring, health information systems, and human capacity development began to show signs of progress toward sustainable country-owned systems. Awareness of the need for and usefulness of data increased, far beyond discussions of indicators and reporting. Emphasis has turned toward ensuring the quality of data and using available data to improve the quality of care. Assessing progress toward an AIDS-free generation requires that the global community can measure the reduction of new HIV infections in children and adults and monitor the coverage, quality, and outcomes of highly efficacious interventions in combination. Building national M&E systems requires sustained efforts over long periods of time with effective leadership and coordination. PEPFAR, in close collaboration with its global and national partners, is well positioned to transform the successes and challenges associated with early rapid scale-up into future opportunities for sustainable, cost-effective, country-owned programs and systems. |
Age-associated DNA methylation in pediatric populations.
Alisch RS , Barwick BG , Chopra P , Myrick LK , Satten GA , Conneely KN , Warren ST . Genome Res 2012 22 (4) 623-32 ![]() DNA methylation (DNAm) plays diverse roles in human biology, but this dynamic epigenetic mark remains far from fully characterized. Although earlier studies uncovered loci that undergo age-associated DNAm changes in adults, little is known about such changes during childhood. Despite profound DNAm plasticity during embryogenesis, monozygotic twins show indistinguishable childhood methylation, suggesting that DNAm is highly coordinated throughout early development. Here we examine the methylation of 27,578 CpG dinucleotides in peripheral blood DNA from a cross-sectional study of 398 boys, aged 3-17 yr, and find significant age-associated changes in DNAm at 2078 loci. These findings correspond well with pyrosequencing data and replicate in a second pediatric population (N = 78). Moreover, we report a deficit of age-related loci on the X chromosome, a preference for specific nucleotides immediately surrounding the interrogated CpG dinucleotide, and a primary association with developmental and immune ontological functions. Meta-analysis (N = 1158) with two adult populations reveals that despite a significant overlap of age-associated loci, most methylation changes do not follow a lifelong linear pattern due to a threefold to fourfold higher rate of change in children compared with adults; consequently, the vast majority of changes are more accurately modeled as a function of logarithmic age. We therefore conclude that age-related DNAm changes in peripheral blood occur more rapidly during childhood and are imperfectly accounted for by statistical corrections that are linear in age, further suggesting that future DNAm studies should be matched closely for age. |
Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008
Deyde V , Garten R , Sheu T , Smith C , Myrick A , Barnes J , Xu X , Shaw M , Klimov A , Gubareva L . Influenza Other Respir Viruses 2009 3 (6) 297-314 ![]() Please cite this paper as: Deyde et al. (2009). Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza and Other Respiratory Viruses 3(6), 297-314.Background Adamantanes resistance in H3N2 viruses has been increasing since 2000, and in 2005-2006 reached nearly 100% in most countries, with the circulation of the N-lineage. In 2006-2007, however, a significant decrease in resistance was observed in many regions. Objectives To explore potential links between adamantane resistance and the A(H3N2) viruses that circulated between 2006 and 2008. Methods A total of 1451 Influenza A (H3N2) viruses collected globally in 2001-2008 were screened for the presence of adamantane resistance markers. A subset of 100 viruses representing the broad genetic and geographic spectrum of these viruses was selected for complete genome sequencing and phylogenetic analyses. Results Full genome sequence analysis of 2006-2007 viruses revealed co-circulation of four distinct genotypes, designated A-D. Phylogenetic analyses demonstrated reassortment between viruses from the N-lineage and other viruses that had circulated in prior seasons, including those bearing an adamantane sensitive marker. Genotype D viruses became dominant in late 2006-2007 and continued to be the main H3N2 genotype in 2007-2008. Viruses of this genotype retained all N-lineage genome segments except PB2 and NP, which were acquired through reassortment. Conclusions The decrease in adamantane resistance at that time was due to transient co-circulation of genotypes that emerged through reassortment. Our findings emphasize the importance of complete genome sequencing in understanding the complex nature of the relationship between influenza virus evolution and antiviral resistance. The recent emergence of the pandemic multi-reassortant H1N1 virus underscores the importance of whole genome sequence monitoring for rapid detection of such unusual and novel strains. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 21, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure